The health of Valeant Pharmaceuticals International Inc’s Michael Pearson is improving, the company said on Thursday, but CNBC reported that there was debate within the board over whether he was ready to return to work.
Pearson, who joined Valeant as chief executive in 2010, was hospitalized with severe pneumonia in late December.
The company named former Chief Financial Officer Howard Schiller as interim CEO in January.
CNBC, citing a source, said Pearson was ready to return but the board was debating whether he should. (bit.ly/20X0uU8)
(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)
NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.
The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.
BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.